Heron earns a second slapdown from the FDA on pain med — shares wither
Intercept wasn’t the only biotech in line for a drubbing today. In addition to the rejection for NASH, Heron Therapeutics $HRTX put out word …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
